

Kerryn Lesley Elliott

Date of Birth: 16th December 1982

Work address:

Institute of Biomedicine
Box 115
40530 Göteborg

Nationality: Australian

E-mail: kerryn.elliott@gu.se

Mobile number: +46 762 456 037

Languages: English (native), Swedish

POST DOCTORAL EXPERIENCE

2016–now Postdoctoral Researcher, The University of Gothenburg, Sweden
Investigating mutational processes and non-coding alterations in cancer

2012–2014: Postdoctoral Researcher, The University of Gothenburg, Sweden
Investigating the interactions of individual subunits of the molecular chaperone CCT

ACADEMIC QUALIFICATIONS:

2006 – 2011: Doctor of Philosophy (PhD)
Structure/ Function studies of the Adenomatous Polyposis Coli Protein

Supervisors: Prof. Tony Burgess, Dr Maree Faux, Dr Meredith Layton

2004: Bachelor of Science Honours (BSc Hons), Grade: H1 (85%)
Characterisation of murine homologs of the Mammalian Ependymin Related Protein

Supervisors: A/Prof Mark Kirkland, Dr Claudia Gregorio-King

2001 – 2003 Bachelor of Science (BSc), Grade: H1 (81%)
The University of Melbourne, Parkville, Victoria, Australia

EMPLOYMENT HISTORY:

2020 – now Senior Researcher, Gothenburg University, Sweden
2016 – 2020 Postdoctoral Researcher, Gothenburg University, Sweden
2014 – 2015 Parental leave
2012 – 2014 Postdoctoral Researcher, Gothenburg University, Sweden
2011 – 2012 Postdoctoral Fellow, Ludwig Institute for Cancer Research, Parkville, Victoria, Australia
2010 – 2011 Casual aquarium staff, Ludwig Institute for Cancer Research, Parkville, Victoria, Australia
1998 – 2005 Laboratory Assistant, Aglab Services, Geelong, Victoria Australia

GRANTS AND AWARDS:

2023	Assar Gabrielsson fond Research Grant	SEK 65,000
2019	Kungl. Vetenskaps- och Vitterhets-Samhället (KVVS)	SEK 12,000
2017	Kungl. Vetenskaps- och Vitterhets-Samhället (KVVS)	SEK 9,000
2017	Stiftelsen Wilhelm och Martina Lundgrens Vetenskapsfond	SEK 10,000
2016	Knut och Alice Wallenbergs Stiftelse	SEK 11000
2014	Stiftelsen Wilhelm och Martina Lundgrens Vetenskapsfond	SEK 20,000
2013 – 2014	Olle Engvist Stiftelse	SEK 140,000
2006 – 2009	Australian Postgraduate Award (APA). Stipend	AUD \$21,000/year

MANUSCRIPTS:

1. Elliott K, Singh VK, Bäckerholm A, Ögren L, Lindberg M, Soczek KM, Hoberg E, Luijts T, Van den Eynden J, Falkenberg M, Doudna J, Ståhlberg A, Larsson E. Mechanistic basis of atypical TERT promoter mutations. *Nat Commun.* 2024;15:9965
2. Elliott K, Singh VK, Bostrom M, Larsson E. Base-resolution UV footprinting by sequencing reveals distinctive damage signatures for DNA-binding proteins. *Nat Commun.* 2023;14(1):2701.
3. Luijts T, Elliott K, Siaw JT, Van de Velde J, Beyls E, Claeys A, et al. A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in normal tissues. *Sci Rep.* 2022;12(1):10322
4. Alaei-Mahabadi B, Elliott K, Larsson E. Systematic investigation of promoter substitutions resulting from somatic intrachromosomal structural alterations in diverse human cancers. *Sci Rep.* 2020;10(1):18176
5. Lindberg M, Bostrom M, Elliott K, Larsson E. Intragenic variability and extended sequence patterns in the mutational signature of ultraviolet light. *Proc Natl Acad Sci U S A.* 2019;116(41):20411-7.
6. Elliott K, Bostrom M, Filges S, Lindberg M, Van den Eynden J, Stahlberg A, et al. Elevated pyrimidine dimer formation at distinct genomic bases underlies promoter mutation hotspots in UV-exposed cancers. *PLoS Genet.* 2018;14(12):e1007849
7. Fredriksson NJ, Elliott K, Filges S, Van den Eynden J, Stahlberg A, Larsson E. Recurrent promoter mutations in melanoma are defined by an extended context-specific mutational signature. *PLoS Genet.* 2017;13(5):e1006773.
8. Elliott KL, Svanstrom A, Spiess M, Karlsson R, Grantham J. A novel function of the monomeric CCTepsilon subunit connects the serum response factor pathway to chaperone-mediated actin folding. *Mol Biol Cell.* 2015;26(15):2801-9.
9. Elliott KL, Catimel B, Church NL, Coates JL, Burgess AW, Layton MJ, et al. Immunopurification of adenomatous polyposis coli (APC) proteins. *BMC Res Notes.* 2013;6:429.

REVIEW ARTICLES:

1. Elliott K, Nilsson J, Van den Eynden J. Pharmacologic RNA splicing modulation: a novel mechanism to enhance neoantigen-directed anti-tumor immunity and immunotherapy response. *Signal Transduct Target Ther.* 2021;6(1):373.
2. Elliott K, Larsson E. Non-coding driver mutations in human cancer. *Nat Rev Cancer.* 2021;21(8):500-9.
3. Lanzos A, Elliott K. EACR Cancer Genomics 2019 conference: from tumour evolution to personalised immunotherapy. *FEBS J.* 2019;286(21):4209-14.